Goro Takeda

Venture Partner

Goro has over 20 years of investment and operating experience in the life science industry. He joined Sofinnova Ventures as a Kauffman Venture Fellow with a focus on assisting Sofinnova portfolio companies develop and execute their Japanese/Asian business development strategy. Goro holds the honor of being the first person from Japan to be selected as a Kauffman Venture Fellow. He is also a co-founder of FinTech Global Capital, an early stage venture capital firm in Tokyo, where he currently serves as Managing Partner.

Before joining Sofinnova Ventures, Goro was the Deputy General Manager of NIF SMBC Ventures, a Japanese venture capital firm with $2 billion under management. Goro was responsible for life science investments across multiple geographic regions.

Goro has been involved with investments in biotechnology companies including Arrow Therapeutics (acquired by AstraZeneca), Cyclacel Pharmaceuticals (CYCC), Intellikine (acquired by Takeda), Ocera Therapuetics (OCRX), Orexigen Therapeutics (OREX), Plexxikon (acquired by Daiichi Sankyo), Prestwick Pharmacueticals (acquired by Biovail), Trius Therapuetics (acquired by Cubist), and iPierian (acquired by BMS).

Prior to launching his career in venture capital, Goro spent nine years in the pharmaceutical industry, most recently as Corporate Officer of the U.S. subsidiary of Tanabe Pharmaceuticals. While in this position, Goro worked on global business development and marketing assignments.

Goro holds a Bachelor of Science in Chemistry from Waseda University and an M.B.A. from the Kellogg Graduate School at Northwestern University.




Representative Investments

  • Intellikine   Acquired - Millennium/Takeda
  • Ocera   Public - (NASDAQ: OCRX)
  • Orexigen   Public - (NASDAQ: OREX)
  • Prestwick   Acquired - Bioval
  • Trius Therapeutics   Acquired - Cubist